Thus, targeting the Gln metabolic network as an Achilles’ heel of PCa offers unique opportunities to tackle therapy resistance and sensitize tumor cells to anticancer treatments and might be more advantageous than targeting AR alone [6,10,12,21,105,108,121,135,137,142,180]. The gene discussed is AR; the disease is neoplasm.